Zymeworks Inc. (NASDAQ:ZYME) Q3 2025 Earnings Call Transcript
Shrinal Inamdar: Thank you, operator. Good afternoon, everyone. Thank you for joining our third quarter 2025 results conference call.
Zymeworks Inc. (ZYME)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 22,970,388 | $604,810,316 | 27.44% | |
| 2. | Rubric Capital Management David Rosen | 5,750,000 | $151,397,500 | +23% | 1.81% |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 3,938,641 | $103,704,418 | 3.49% | |
| 4. | Perceptive Advisors Joseph Edelman | 3,261,850 | $85,884,511 | +57% | 1.53% |
| 5. | Siren L.L.C. Raymond Debbane | 1,680,121 | $44,237,586 | 1.32% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.78 | 5,919 | $69,738.25 | 17,883,908 | 2025-05-19 | Filing | |
| $11.43 | 49,502 | $565,847.46 | 17,877,989 | 2025-05-15 | Filing | |
| $11.52 | 54,760 | $630,818.77 | 17,828,487 | 2025-04-17 | Filing | |
| $11.16 | 73,953 | $825,589.11 | 17,773,727 | 2025-04-16 | Filing | |
| $11.17 | 196,438 | $2,193,799.94 | 17,699,774 | 2025-04-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.67 | 6,120 | $138,761.82 | 132,913 | 2026-01-12 | Filing | |
| $22.67 | 9,310 | $211,090.29 | 26,708 | 2026-01-12 | Filing | |
| $22.67 | 9,560 | $216,758.66 | 48,497 | 2026-01-12 | Filing | |
| $22.67 | 30,424 | $689,818.56 | 226,842 | 2026-01-12 | Filing | |
| $25.10 | 10,538 | $264,471.13 | 18,352 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,595,548 | $121,000,779 | 0% | |
| 2. | 2,593,080 | $68,275,801 | 0% | |
| 3. | 2,328,727 | $61,315,382 | 0% | |
| 4. | 1,595,833 | $42,018,282 | 0.01% | |
| 5. | 1,159,215 | $30,523,404 | 0.01% |
News See All
Zymeworks Inc. (NASDAQ:ZYME) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by. This is the conference operator. Welcome to Zymeworks Second Quarter 2025 Results Conference Call and Webcast.
Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by. This is the conference operator. Welcome to Zymeworks First Quarter 2025 Results Conference Call and Webcast.
Zymeworks Inc. (NYSE:ZYME) Q4 2024 Earnings Call Transcript
Operator: Thank you for standing by. This is the conference operator. Welcome to Zymeworks Fourth Quarter and Year-end 2024 Results Conference Call and Webcast.
Zymeworks Inc. (NYSE:ZYME) Q3 2024 Earnings Call Transcript
Operator: Hello. Thank you for standing by. This is the conference operator. Welcome to Zymeworks First Quarter 2024 Results Conference Call and Webcast.
Zymeworks Inc. (NYSE:ZYME) Q2 2024 Earnings Call Transcript
Operator: Thank you for standing by. This is the conference operator. Welcome to Zymeworks Second Quarter 2024 Results Conference Call and Webcast.
Zymeworks Inc. (NYSE:ZYME) Q1 2024 Earnings Call Transcript
Zymeworks Inc. misses on earnings expectations. Reported EPS is $-0.41513 EPS, expectations were $-0.31. Zymeworks Inc.
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds.
Zymeworks Inc. (NYSE:ZYME) Q4 2023 Earnings Call Transcript
Zymeworks Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.39. Zymeworks Inc.
18 High Growth Low PE Stocks
When value stocks came back with a vengeance in 2022, value investors cheered what they thought was the beginning of a long bull run of value stocks.
Hedge Fund Resource Center Billionaire Hedge Funds
